Novavax and Commonwealth of Australia announce agreement in principle for acquisition of Novavax COVID-19 vaccine

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business and Industry Source Type: news